2014.09.15
new SNU breast cancer cell lines 세포주 분양개시
7종류의 새로운 SNU breast cancer cell lines에 대한 특성분석 논문이 등록되었습니다. 아울러 세포주 분양도 실시합니다. 당분간은 culture only로만 분양됩니다. '세포주검색-pdf파일서비스'에서 다운로드 받으세요.
2013.06.07
SNU-2535, EML4-ALK positive lung cancer cell line 보고
J Thorac Oncol. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS. Source Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Abstract BACKGROUND: Anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is markedly sensitive to the ALK inhibitor crizotinib. However, acquired resistance to crizotinib is inevitable through several mechanisms. Therefore, this study was conducted to identify genetic alterations associated with crizotinib resistance. METHODS: Tumor samples were derived from seven ALK-positive NSCLC patients who showed acquired resistance to crizotinib, and these patients were analyzed for ALK, EGFR, and KRAS mutations and ALK and EGFR gene amplifications. In vitro cytotoxicity of crizotinib and ALK downstream signals were compared between crizotinib-naive and -resistant NSCLC cells. RESULTS: After a median duration of 6 months (range, 4-12 months), seven ALK-positive NSCLC patients developed acquired resistance to crizotinib. Three patients harbored secondary ALK mutations, including one patient with both mutations: L1196M (n = 2) and G1269A (n = 2). Of note, one patient displayed ALK gene copy number gain (4.1-fold increase compared with the pre-crizotinib specimen) and EGFR L858R mutation with high polysomy. The amphiregulin concentration was high in the supernatant fluid from five patients with malignant pleural effusion (116.4-18934.0 pg/ml). SNU-2535 cells derived from a patient who harbored the G1269 mutation were resistant to crizotinib treatment similar to H3122 CR1 cells. L1196M and G1269A mutant clones were less sensitive to crizotinib and ALK downstream signals were ineffectively suppressed in these clones. CONCLUSIONS: Genetic changes associated with crizotinib resistance are heterogeneous in ALK-rearranged NSCLC patients who respond to crizotinib and subsequently develop resistance. PMID: 23344087 [PubMed - in process] Publication Types
2011.07.12
SNU lung cancer cell lines 논문
6종류의 새로운 SNU lung cancer cell lines에 대한 논문이 특성분석 논문이 등록되었습니다. '세포주검색-pdf파일서비스'에서 다운로드 받으세요.
2024.09.06
** 2024년 9,10월 분양 일정 안내 **
이어지는 공휴일로, 세포주의 안전한 도착 보장을 위해다음과 같이 분양을 진행합니다.(10/7)월요일 택배분양 공휴일로 인해 지역마다 도착지연이 발생될수 있습니다.분양 신청에 참고하여 주시고문의사항이 있으실 경우전화 : 02-3668-7915, 010-2107-7915메일 : kclb@kclb.kr및 한국세포주은행 카카오채널로 연락주시기 바랍니다.감사합니다.
2022.07.21
거래명세서와 견적서의 '공급받는자' 정보부분
거래명세서와 견적서의 '공급받는자' 정보부분은마이페이지-회원정보수정에서, 사업자정보란에 발급 원하시는 기관의 정보를 입력해 주셔야합니다.'정보가 없을경우' 공란으로 나오며, 마이페이지에서 수정하시면 정보가 입력됩니다. 참고하여 주시면 감사하겠습니다.
2022.03.07
** 3D 오가노이드를 활용한 HTS(High Throughput Screening) 서비스 안내 **
** 3D 오가노이드를 활용한 HTS(High Throughput Screening) 서비스 안내 ** 한국세포주은행에서는 3D 오가노이드를 활용한 high throughput drug screening service를 지원합니다. 2D 세포주 및 3D 오가노이드에 대한 drug screening 비교 service도 가능합니다. 오가노이드를 활용한 drug screening service에 대한 자세한 내용은 이메일(kclb@kclb.kr)이나 카카오채널로 문의하여 주시면 자세한 절차 안내해드리겠습니다. 감사합니다.
Korean Cell Line Bank, Korean Cell Line Research Foundation,
Seoul National University Samsung Cancer Research Building (Yeongeon-dong),
101, Daehak-ro, Jongno-gu, Seoul, 03080, Korea
대표자 : 박재갑 | 개인정보보안책임자 : 신영경 | 사업자 등록번호 : 208-82-03887
통신판매업 신고 제2015-서울혜화-0125호 | Tel : 82-2-3668-7915 | Fax : 82-2-742-0021 | Email : kclb@kclb.kr
KCLB (C) is a registered mark of Korean Cell Line Bank. All rights reserved. 1998~2015